Stock QURE UNIQURE N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Company uniQure N.V.

Equities

QURE

NL0010696654

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
4.95 USD +5.77% Intraday chart for uniQure N.V. +3.99% -26.88%
May. 08 Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating MT
May. 07 UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Number of employees: 480

Sales per Business

USD in Million2022Weight2023Weight Delta
Gene Therapies
100.0 %
106 100.0 % 16 100.0 % -85.12%

Managers

Managers TitleAgeSince
Matt Kapusta CEO
 Chief Executive Officer 51 14-12-31
Christian Klemt DFI
 Director of Finance/CFO 51 14-12-31
Pierre Caloz COO
 Chief Operating Officer 52 21-05-16
Richard Porter CTO
 Chief Tech/Sci/R&D Officer - 21-06-30
Jeannette Potts CMP
 Compliance Officer 62 -
Walid Abi-Saab CTO
 Chief Tech/Sci/R&D Officer 59 23-06-25
Robert Gut BRD
 Director/Board Member 59 18-06-12
Maria E. Cantor IRO
 Public Communications Contact 56 16-06-26
Erin Boyer HRO
 Human Resources Officer - 22-03-31

Members of the board

Members of the board TitleAgeSince
Leonard Post BRD
 Director/Board Member 72 20-06-16
Jack Kaye BRD
 Director/Board Member 80 16-06-14
Jeremy Springhorn BRD
 Director/Board Member 61 17-09-13
Matt Kapusta CEO
 Chief Executive Officer 51 14-12-31
David Meek CHM
 Chairman 59 18-06-12
Madhavan Balachandran BRD
 Director/Board Member 73 17-09-13
Paula Soteropoulos BRD
 Director/Board Member 56 13-06-30
Robert Gut BRD
 Director/Board Member 59 18-06-12
Jacques Suzanne BRD
 Director/Board Member 53 21-10-20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 48,549,437 46,469,239 ( 95.72 %) 0 95.72 %

Shareholders

NameEquities%Valuation
Vestal Point Capital LP
9.877 %
4,725,000 9.877 % 21 M $
Nantahala Capital Management LLC
6.455 %
3,088,082 6.455 % 14 M $
683 Capital Management LLC
4.128 %
1,975,000 4.128 % 9 M $
BlackRock Advisors LLC
3.418 %
1,635,129 3.418 % 7 M $
Morgan Stanley Capital Services LLC
3.174 %
1,518,228 3.174 % 7 M $
International Biotechnology Trust Plc
2.595 %
1,241,500 2.595 % 6 M $
Schroder Investment Management Ltd. (13F Subfiler)
2.595 %
1,241,500 2.595 % 6 M $
Vanguard Global Advisers LLC
2.242 %
1,072,536 2.242 % 5 M $
JPMorgan Securities LLC
2.027 %
969,504 2.027 % 4 M $
D.E. Shaw & Co., Inc.
1.777 %
850,100 1.777 % 4 M $

Company contact information

uniQure NV

Paasheuvelweg 25a

1105 BP, Amsterdam

+31 20 240 6000

http://www.uniqure.com
address uniQure N.V.(QURE)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for uniQure N.V.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
4.564 EUR
Average target price
17.09 EUR
Spread / Average Target
+274.40%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
UNIQURE N.V. Stock uniQure N.V.
-26.88% 240M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. QURE Stock
  4. Company uniQure N.V.